| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
53,065,000 |
| Market
Cap: |
5.86(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$54.85 - $111.39 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Glaukos is an ophthalmic medical technology and pharmaceutical company focused on developing therapies for the treatment of glaucoma, corneal disorders, and retinal disease. Co. has developed Micro-Invasive Glaucoma Surgery to serve as an alternative to the glaucoma treatment paradigm, a bio-activated pharmaceutical therapy for the treatment of a corneal disorder, keratoconus, as well as a pipeline of surgical devices, sustained pharmaceutical therapies, and implantable biosensors to treat glaucoma progression, corneal disorders such as keratoconus, dry eye and refractive vision correction, and retinal diseases such as neovascular age-related macular degeneration and retinal vein occlusion.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
96,807 |
640,824 |
870,965 |
894,185 |
| Total Sell Value |
$9,573,149 |
$55,563,574 |
$72,324,270 |
$73,696,165 |
| Total People Sold |
4 |
6 |
6 |
6 |
| Total Sell Transactions |
19 |
43 |
58 |
65 |
| End Date |
2024-02-29 |
2023-11-28 |
2023-05-30 |
2022-05-30 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Weisner Aimee S |
Director |
– • – |
2021-06-03 |
4 |
A |
$0.00 |
$0 |
D/D |
2,382 |
16,887 |
|
- |
|
| Foley Mark J |
Director |
– • – |
2021-06-03 |
4 |
A |
$0.00 |
$0 |
D/D |
2,382 |
14,752 |
|
- |
|
| Link William J Phd |
Director |
– • – |
2021-06-03 |
4 |
A |
$0.00 |
$0 |
D/D |
2,382 |
17,821 |
|
- |
|
| Stapley Marc |
Director |
– • – |
2021-06-03 |
4 |
A |
$0.00 |
$0 |
D/D |
2,382 |
20,064 |
|
- |
|
| Hoffmeister David F |
Director |
– • – |
2021-06-03 |
4 |
A |
$0.00 |
$0 |
D/D |
2,382 |
19,010 |
|
- |
|
| Torres Denice |
Director |
– • – |
2021-06-03 |
4 |
A |
$0.00 |
$0 |
D/D |
2,382 |
5,910 |
|
- |
|
| Wen Leana |
Director |
– • – |
2021-06-03 |
4 |
A |
$0.00 |
$0 |
D/D |
2,382 |
5,910 |
|
- |
|
| Kliman Gilbert H |
Director |
– • – |
2021-06-03 |
4 |
A |
$0.00 |
$0 |
D/D |
2,382 |
8,776 |
|
- |
|
| Gilliam Joseph E |
CFO, SVP Corporate Development |
• – – |
2021-05-06 |
4 |
AS |
$81.95 |
$411,090 |
D/D |
(5,000) |
37,190 |
|
-37% |
|
| Gilliam Joseph E |
CFO, SVP Corporate Development |
• – – |
2021-05-06 |
4 |
D |
$82.63 |
$871,664 |
D/D |
(10,549) |
42,190 |
|
- |
|
| Gilliam Joseph E |
CFO, SVP Corporate Development |
• – – |
2021-05-03 |
4 |
AS |
$93.18 |
$1,870,659 |
D/D |
(20,000) |
52,739 |
|
-44% |
|
| Gilliam Joseph E |
CFO, SVP Corporate Development |
• – – |
2021-05-03 |
4 |
OE |
$30.92 |
$571,500 |
D/D |
15,000 |
72,739 |
|
- |
|
| Burns Thomas William |
Chief Executive Officer |
• • – |
2021-03-22 |
4 |
D |
$88.85 |
$396,688 |
D/D |
(4,457) |
353,705 |
|
- |
|
| Gilliam Joseph E |
CFO, SVP Corporate Development |
• – – |
2021-03-22 |
4 |
D |
$89.22 |
$50,142 |
D/D |
(562) |
57,739 |
|
- |
|
| Calcaterra Chris M. |
Chief Operating Officer |
• – – |
2021-03-18 |
4 |
D |
$89.22 |
$69,859 |
D/D |
(783) |
178,522 |
|
- |
|
| Calcaterra Chris M. |
Chief Operating Officer |
• – – |
2021-03-18 |
4 |
A |
$0.00 |
$0 |
D/D |
15,499 |
179,305 |
|
- |
|
| Burns Thomas William |
Chief Executive Officer |
• • – |
2021-03-18 |
4 |
A |
$0.00 |
$0 |
D/D |
38,247 |
356,314 |
|
- |
|
| Gilliam Joseph E |
CFO, SVP Corporate Development |
• – – |
2021-03-18 |
4 |
A |
$0.00 |
$0 |
D/D |
15,499 |
58,301 |
|
- |
|
| Gilliam Joseph E |
CFO, SVP Corporate Development |
• • – |
2021-03-15 |
4 |
AS |
$87.88 |
$439,400 |
D/D |
(5,000) |
42,802 |
|
-44% |
|
| Gilliam Joseph E |
CFO, SVP Corporate Development |
• • – |
2021-03-15 |
4 |
OE |
$39.10 |
$195,500 |
D/D |
5,000 |
47,802 |
|
- |
|
| Kliman Gilbert H |
Director |
– • – |
2021-03-03 |
4 |
A |
$0.00 |
$0 |
D/D |
680 |
6,394 |
|
- |
|
| Kliman Gilbert H |
Director |
– • – |
2021-03-03 |
4 |
D |
$0.00 |
$0 |
I/I |
(303,000) |
0 |
|
- |
|
| Kliman Gilbert H |
Director |
– • – |
2021-03-03 |
4 |
A |
$0.00 |
$0 |
I/I |
3,000 |
3,000 |
|
- |
|
| Torres Denice |
Director |
– • – |
2021-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
3,528 |
3,528 |
|
- |
|
| Wen Leana |
Director |
– • – |
2021-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
3,528 |
3,528 |
|
- |
|
541 Records found
|
|
Page 11 of 22 |
|
|
1.04 (0.95%) 
